Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...
People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...
How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
SAN DIEGO — Results from two phase 3 trials offer mixed findings on the potential of experimental Bruton tyrosine kinase (BTK) inhibitors for primary progressive multiple sclerosis (PPMS). Findings ...
A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid ...
Process mining and representation learning applied to 447,222 patients revealed nuanced pre-diagnostic pathways associated with delayed MS diagnosis, implicating referral friction, misdiagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results